Cargando…

Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

It has been well established that the etiopathogenesis of diverse autoimmune diseases is rooted in the autoreactive immune cells’ excessively proliferative state and impaired apoptotic machinery. Survivin is an anti-apoptotic and mitotic factor that has sparked a considerable research interest in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shomali, Navid, Suliman Maashi, Marwah, Baradaran, Behzad, Daei Sorkhabi, Amin, Sarkesh, Aila, Mohammadi, Hamed, Hemmatzadeh, Maryam, Marofi, Faroogh, Sandoghchian Shotorbani, Siamak, Jarahian, Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927965/
https://www.ncbi.nlm.nih.gov/pubmed/35309327
http://dx.doi.org/10.3389/fimmu.2022.839945
_version_ 1784670557964337152
author Shomali, Navid
Suliman Maashi, Marwah
Baradaran, Behzad
Daei Sorkhabi, Amin
Sarkesh, Aila
Mohammadi, Hamed
Hemmatzadeh, Maryam
Marofi, Faroogh
Sandoghchian Shotorbani, Siamak
Jarahian, Mostafa
author_facet Shomali, Navid
Suliman Maashi, Marwah
Baradaran, Behzad
Daei Sorkhabi, Amin
Sarkesh, Aila
Mohammadi, Hamed
Hemmatzadeh, Maryam
Marofi, Faroogh
Sandoghchian Shotorbani, Siamak
Jarahian, Mostafa
author_sort Shomali, Navid
collection PubMed
description It has been well established that the etiopathogenesis of diverse autoimmune diseases is rooted in the autoreactive immune cells’ excessively proliferative state and impaired apoptotic machinery. Survivin is an anti-apoptotic and mitotic factor that has sparked a considerable research interest in this field. Survivin overexpression has been shown to contribute significantly to the development of autoimmune diseases via autoreactive immune cell overproliferation and apoptotic dysregulation. Several microRNAs (miRNAs/miRs) have been discovered to be involved in survivin regulation, rendering the survivin-miRNA axis a perspective target for autoimmune disease therapy. In this review, we discuss the role of survivin as an immune regulator and a highly implicated protein in the pathogenesis of autoimmune diseases, the significance of survivin-targeting miRNAs in autoimmunity, and the feasibility of targeting the survivin-miRNA axis as a promising therapeutic option for autoimmune diseases.
format Online
Article
Text
id pubmed-8927965
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89279652022-03-18 Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies Shomali, Navid Suliman Maashi, Marwah Baradaran, Behzad Daei Sorkhabi, Amin Sarkesh, Aila Mohammadi, Hamed Hemmatzadeh, Maryam Marofi, Faroogh Sandoghchian Shotorbani, Siamak Jarahian, Mostafa Front Immunol Immunology It has been well established that the etiopathogenesis of diverse autoimmune diseases is rooted in the autoreactive immune cells’ excessively proliferative state and impaired apoptotic machinery. Survivin is an anti-apoptotic and mitotic factor that has sparked a considerable research interest in this field. Survivin overexpression has been shown to contribute significantly to the development of autoimmune diseases via autoreactive immune cell overproliferation and apoptotic dysregulation. Several microRNAs (miRNAs/miRs) have been discovered to be involved in survivin regulation, rendering the survivin-miRNA axis a perspective target for autoimmune disease therapy. In this review, we discuss the role of survivin as an immune regulator and a highly implicated protein in the pathogenesis of autoimmune diseases, the significance of survivin-targeting miRNAs in autoimmunity, and the feasibility of targeting the survivin-miRNA axis as a promising therapeutic option for autoimmune diseases. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8927965/ /pubmed/35309327 http://dx.doi.org/10.3389/fimmu.2022.839945 Text en Copyright © 2022 Shomali, Suliman Maashi, Baradaran, Daei Sorkhabi, Sarkesh, Mohammadi, Hemmatzadeh, Marofi, Sandoghchian Shotorbani and Jarahian https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Shomali, Navid
Suliman Maashi, Marwah
Baradaran, Behzad
Daei Sorkhabi, Amin
Sarkesh, Aila
Mohammadi, Hamed
Hemmatzadeh, Maryam
Marofi, Faroogh
Sandoghchian Shotorbani, Siamak
Jarahian, Mostafa
Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
title Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
title_full Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
title_fullStr Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
title_full_unstemmed Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
title_short Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
title_sort dysregulation of survivin-targeting micrornas in autoimmune diseases: new perspectives for novel therapies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927965/
https://www.ncbi.nlm.nih.gov/pubmed/35309327
http://dx.doi.org/10.3389/fimmu.2022.839945
work_keys_str_mv AT shomalinavid dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT sulimanmaashimarwah dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT baradaranbehzad dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT daeisorkhabiamin dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT sarkeshaila dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT mohammadihamed dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT hemmatzadehmaryam dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT marofifaroogh dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT sandoghchianshotorbanisiamak dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies
AT jarahianmostafa dysregulationofsurvivintargetingmicrornasinautoimmunediseasesnewperspectivesfornoveltherapies